Alkermes (ALKS) Share-based Compensation Growth (3y) (2013 - 2026)
Alkermes (ALKS) Share-based Compensation Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 10.06% |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 9.14% |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 0.43% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | -8.13% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | -1.73% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | -8.04% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | 50.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.55% |
| Mar 31, 2026 | 76.17% |
| Dec 31, 2025 | 99.68% |
| Sep 30, 2025 | -71.20% |
| Jun 30, 2025 | 15.51% |
| Mar 31, 2025 | 154.33% |
| Dec 31, 2024 | 2.94% |
| Sep 30, 2024 | -40.03% |
| Jun 30, 2024 | -47.91% |
| Mar 31, 2024 | 76.18% |
| Dec 31, 2023 | 1.27% |
| Sep 30, 2023 | 1.87% |
| Jun 30, 2023 | 33.36% |
| Mar 31, 2023 | -2.19% |
| Dec 31, 2022 | -46.36% |
| Sep 30, 2022 | -0.85% |
| Jun 30, 2022 | 99.04% |
| Mar 31, 2022 | -44.59% |
| Dec 31, 2021 | 3.61% |
| Sep 30, 2021 | 0.70% |